Downloading...
Download

ADMA

ADMA Biologics, Inc. (ADMA) – Plasma Power with Policy TailwindsCompany Snapshot: ADMA Biologics NASDAQ:ADMA is carving out a dominant position in plasma-derived immunotherapies, with a 100% U.S.-based supply chain that delivers both regulatory resilience and logistical strength in a vital healthcare segment. Key Catalysts: Strategic Domestic Advantage 🇺🇸 Fully U.S.-based manufacturing and supply chain Aligns with national healthcare policy and reduces global exposure risk Elite Healthcare Partnerships 🏥 Works with Mayo Clinic & Cleveland Clinic Validates product quality and ensures recurring revenue streams Strong Insider Conviction 📈 CEO Adam Grossman purchased $1.2M in stock Insiders own 12%, showing long-term commitment Plasma Therapy Demand on the Rise 🚨 Growing market for immune deficiency and infectious disease treatments Reliable production scale + strategic partnerships = compounding value Investment Outlook: ✅ Bullish Above: $19.00–$20.00 🚀 Target Range: $29.00–$30.00 🔑 Thesis: Fully domestic moat + institutional partnerships + insider alignment = high-conviction growth biotech 📢 ADMA: A rare mid-cap with stability, growth, and a policy-aligned advantage. #BiotechStocks #PlasmaTherapy #Immunology #ADMA #InsiderBuying #HealthcareMoat
NASDAQ:ADMALong
by Richtv_official
ADMA at 50 on Fib RetracementADMA is hovering around the 50 retracements with a lot of sell orders on the books probably from people trying to get out at 1.90. Buy orders look good though in the face of this massive sell-off. This is was after news dropped that analysts saw the price between 6 and 11 dollars. Although ADMA has been struggling to turn a profit most of these reasons have been to position themselves for the infrastructure necessary to start pulling in good returns. This FDA approval is looking more and more like the catalyst necessary to break through 3 dollars.
NASDAQ:ADMALong
by DiastoAle
ADMA Technical Analysis 🧙ADMA Biologics Inc is a United States-based biopharmaceutical company. It is engaged in the manufacture, marketing and development of specialty plasma-derived biologics. The operating segments of the company are ADMA BioManufacturing segment; Plasma Collection Centers segment; and Corporate segment. The Plasma Collection Centers segment consists of three FDA-licensed source plasma collection facilities located in Georgia. The company's ADMA BioManufacturing segment reflects the company's immune globulin manufacturing and development operations in Florida. If you understand the idea,🎯 press a thumb up! 👍 Have a question? Don't be shy to ask! 🤓 Interested to study how to analyze charts, follow me!
NASDAQ:ADMALong
by trading_as_bus
Stay out when Line L is broken to protect your portfolio!Stay out when Line L is broken to protect your portfolio! What is Line L? Line L is a horizontal line that connects the security lowest price reached previously and later retested and penetrated. Never average into a stock when you see Line L is broken. If you average into a stock when the price plunge after Line L is broken you will amplify your losses significantly. Let me give you an example. With the weekly chart of ADMA, you can see Line L is broken on Feb 23, 2015, followed by -$2.35 drop that is -23.94% of your portfolio. This happened again on Dec 28, 2015, followed by -$3.66 drop that is -46.50% of your portfolio. Again, this happened on May 8, 2017, followed by -$2.00 drop that is -48.16% of your portfolio. This pattern repeated on Dec 10, 2018, followed by -$2.48 that is -54.94% of your portfolio. Lastly, on Feb 3, 2020, Line L is broken followed by -$1.46 that is -$43.18%. Currently, Line L is at around $1.75, if Line L is broken again at $1.75 then there is a high probability the stock may be more bearish once the price breakout of this descending triangle pattern. I used the market probe price level to determine the price for my Line L. A market probe is a way for the bulls and bears to measure the market desire to advance further in the current trend direction or not. For an explanation of a market probe, please read my article on December 12, 2020, with the title, "A Market Probe versus A Shadow." Thank you for reading! Please click Like and click Follow to see more articles and examples. Greenfield Disclosure: Just a market opinion by Greenfield Analysis LLC for educational purposes. This is not a recommendation. Greenfield Analysis LLC has no investment in any of the securities mentioned in the article, and no plan to initiate a trade in any of the securities mentioned. Investment involves substantial risk. You should consider carefully before making an investment. Investment at your own risk.
NASDAQ:ADMA
by GreenfieldAnalysis
Stock update for ADMA! +6.63% Today Stock update for ADMA! +6.63% Today The stock symbol ADMA had a large market move today +6.63% that is close enough to my price target call of $2.12 on Dec 7, 2020 (please check my previous article on Dec 7, 2020). Remember what I said earlier, the stock must prove itself a winner by staying above $2.12. Currently, I have a short-term price target of $2.40. However, be careful of market volatility, I will remember to place a stop at $1.89. If the stock to trade lower than $1.80 on high volume, then there is a chance the bears will short sell the stock to the previous low of $1.55 or to a new low. Just a humble market opinion by Greenfield Analysis. This is not a recommendation. Greenfield Analysis has no investment in ADMA, no plan to initiate a trade-in ADMA and does not receive any compensation for this market opinion. Please click like and follow to see more. Thank you for reading. Greenfield
NASDAQ:ADMALong
by GreenfieldAnalysis
ADMA, A major test to watch!!!A major test to watch!!! ADMA just formed an island. Can AMDA move above $2.12 and hold the price above $2.12? ADMA just formed an island pattern. On Nov 5, 2020, ADMA had a bear gap, and on Dec 1, 2020, ADMA retested the previous price level of $2.12. Can the bulls move the price above $2.12 and hold the price above $2.12? A short-term price reversal may be coming if the bulls can move the price above $2.12! Just a humble market opinion by Greenfield Analysis. Greenfield Analysis has no investment in ADMA, no plan to initiate a trade-in ADMA and does not receive any compensation for this market opinion. Greenfield Analysis
NASDAQ:ADMA
by GreenfieldAnalysis
1